News Story: Full Text
Sponsored By
Please Click On The Above Banner For More Details
Braintumor Website

Allos` brain cancer drug flops in phase 3

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 06/20/2007

RSS Feed - Health Business - Briefing
Published: June 19, 2007 at 2:48 PM
E-mail Story | Print Preview | License

WESTMINSTER, Colo., June 19 (UPI) -- U.S. firm Allos Therapeutics said Tuesday it has disappointing data from a study of efaproxyn in women with breast cancer-originating brain cancer.

The company said it would discontinue developing the drug, based on results from its phase 3, ENRICH study of efaproxyn in combination with whole brain radiation, where the drug failed to achieve its primary endpoint of statistically significant improvement in overall survival in patients who have brain metastases that originated from breast cancer.

Allos said it would turn its attention to pralatrexate (PDX), the drug it is developing for relapsed or refractory peripheral T-cell lymphoma.

"Although we are disappointed with the results of the ENRICH study, we are excited about the potential of our product pipeline," said Pablo Cagnoni, Allos' chief medical officer. "We expect to provide the next update on our PDX PROPEL study later this year following completion of a pre-specified interim analysis of response data after 35 patients have completed at least one cycle of treatment with PDX."


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557